EVGN

Evogene Ltd.

0.55 USD

Last updated Sep 12, 05:26 UTC

Yesterday HIGH

$0.51

Yesterday LOW

$0.48

52w HIGH

$1.5

52w LOW

$0.37

EPS

-0.13

PE

-4.22

Next Earnings

Nov 19, 2026

Overview News Insider Transactions Government Trades Fundamentals

Evogene Ltd. stock is down -15.66% since 30 days ago. The next earnings date is Nov 19, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 September’s closed higher than August.

Benzinga Newsdesk

Wed Jun 24, 2026

Evogene Completes Milestone In Second Collab With Google Cloud, Integration Of Agentic Computational Systems Within Its ChemPass AI Platform
Benzinga Insights

Wed Jun 24, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-market session. The company's market cap stands at $22.1 million. Catheter Precision (AMEX:VTAK) shares rose 44.56% to
Benzinga Insights

Thu Jun 11, 2026

Full Transcript: Evogene Q1 2026 Earnings Call
Benzinga Newsdesk

Tue Jun 2, 2026

Evogene shares are trading lower. The company announced completion of the first-in-human Phase 1 clinical study of BMC128 in combination with Nivolumab in patients with advanced solid tumors.
Benzinga Newsdesk

Tue Jun 2, 2026

Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical ActivityREHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN), a pioneering
Benzinga Newsdesk

Tue Jun 2, 2026

Evogene Reports Early Results for Cancer Therapy Study, Experimental Treatment Meets Safety Goal in First Human Trial

Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced
Benzinga Newsdesk

Wed May 20, 2026

Evogene Files Secondary Offering Of 2,446,707 Shares By Selling Shareholder

- SEC filing
Benzinga Insights

Wed May 20, 2026

Earnings Scheduled For May 20, 2026
Benzinga Newsdesk

Wed May 20, 2026

Evogene Q1 EPS $(0.60) Misses $(0.27) Estimate, Sales $334.000K Miss $350.000K Estimate

Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.27) by 122.22 percent. This is a 57.89 percent decrease over losses of $(0.38) per share from the
Benzinga Newsdesk

Thu Apr 2, 2026

Evogene Receives Nasdaq Noncompliance Notification, Gets Time Through Sept. 28 To Regain Compliance

Evogene Ltd. (NASDAQ:EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural

Gabi Tarcic, Chief Development Officer

Thu Jun 4, 2026

EVGN Recent Insider Trades and Stock Chart

1,129 shares bought
LEON RECANATI, Director

Tue Aug 11, 2026

EVGN Recent Insider Trades and Stock Chart

460,000 shares bought